研究cathelicidin-DM在肝癌中的抗癌功能和机制
Huang Hu1, Jingjing Tai1, Ruiyun Zhang2
1School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou 310018, China; Jinhua University of Vocational Technology, Agriculture College, Jinhua 321016, China.
Genomics
|April 27, 2025
概括
皮皮中的基素-DM (C-DM) 有效地抑制肝癌 (LC) 细胞的生长和迁移. 通过降低DHRS3和JAK-STAT通路的调节,C-DM显示出作为一种新型治疗剂的前景.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青皮肤中的生物活性分子表现出抗癌特性.
- 凯瑟利西丁-DM (C-DM) 是一种青皮肤,对瘤细胞的影响尚不清楚.
研究的目的:
- 研究C-DM对肝癌 (LC) 细胞的抗瘤作用.
- 阐明C-DM在LC中的作用背后的分子机制.
主要方法:
- 细胞活力测试 (CCK-8),殖民地形成,流细胞计和Transwell测试被用来评估C-DM对LC细胞的影响.
- 异种移植模型评估了C-DM在体内抗瘤活性.
- RNA-seq和基因组丰富分析 (GSEA) 确定了差异表达的基因 (DEG) 和途径.
主要成果:
- 在HepG2和Hep3B细胞中,C-DM显著抑制了细胞增殖,迁移,入侵和细胞周期进展,同时促进了HepG2和Hep3B细胞的亡.
- 在体内研究证实了C-DM的抗瘤疗效,毒性低.
- C-DM降低了DHRS3的调节,发现DHRS3促进LC恶性瘤并激活JAK-STAT通路.
结论:
- C-DM显示出显著的抗肝癌效应.
- 该机制涉及降低DHRS3的调节,并抑制JAK-STAT通路.
- C-DM代表了肝癌治疗的潜在治疗候选者.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.7K
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.4K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K